The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

Komal Jhaveria Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
View further author information

Howard A Burris 3rdc Department of Investigational Cancer Therapeutics, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USAView further author information

Timothy A Yapd Department of Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USAView further author information

Erika Hamiltonc Department of Investigational Cancer Therapeutics, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USAView further author information

Hope S Rugoe Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USAView further author information

Jonathan W Goldmanf David Geffen School of Medicine at UCLA, Los Angeles, CAView further author information

Stephen Danng Pfizer Inc., New York, NY, USAView further author information

Feng Liug Pfizer Inc., New York, NY, USAView further author information

Gilbert Y Wongg Pfizer Inc., New York, NY, USAView further author information

Heike Krupkag Pfizer Inc., New York, NY, USAView further author information

Geoffrey I Shapiroh Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information

show all